Key facts
- This page summarizes Arnold C. Hanish's Form 4 filing for Decoy Therapeutics Inc. (DCOY).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Sep 2026, 17:45.
Arnold C. Hanish - 31 Aug 2026 Form 4 Insider Report for Decoy Therapeutics Inc. (DCOY)
- Reporting relationship
- Director
- Issuer ticker
- DCOY
- Reported as of
- 31 Aug 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Sep 2026, 17:45:02 UTC
- Prior SEC filing
- 28 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/Mark Rosenblum, as Attorney -in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Arnold C. Hanish filed Form 4 for Decoy Therapeutics Inc. (DCOY) on 02 Sep 2026.
Change
- Previous filing in this sequence was filed on 28 Aug 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001233253
Primary reporting owner
HANISH ARNOLD C
- Relationship
- Director
- Address
- 2450 HOLCOMBE BLVD STE X, HOUSTON
- Signature
- /s/Mark Rosenblum, as Attorney -in-Fact
- Signature date
- 02 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DCOY
transaction
Common Stock
Award
- Transaction value
- Shares
- +3,000
- Change %
- +718%
- Price
- $0.000000*
- Shares after
- 3,418
- Date
- 31 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
Footnote F2
Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock split effective on March 6, 2026.